A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 205-212

  Wang, Yan ^a   Ma, Jingyi ^a   Chow, Sheung Ching ^b   Li, Chi Han ^b   Xiao, Zhangang ^b   Feng, Ru ^a   Fu, Jie ^a   Chen, Yangchao ^b,c  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Prince of Wales Hospital   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticancer drug; Enhancer of zeste homolog 2; Hepatocellular carcinoma; Traditional Chinese medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DAVIDIIN; DOXORUBICIN; ELLAGITANNIN; FLUOROURACIL; PLANT EXTRACT; POLYGONUM CAPITATUM EXTRACT; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; MTT ASSAY; NONHUMAN; POLYGONUM; POLYGONUM CAPITATUM; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROLYZABLE TANNINS; LIVER NEOPLASMS; MALE; MICE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEASOME ENDOPEPTIDASE COMPLEX; TANNINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893811289     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1025-3     Document Type: Article

References (26)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-43.
2. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124-34.
3. Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 2012;32:1379-86.
4. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2:45-59.
5. Song LR, Ding XL, Zang ZY, Hong X. Dictionary of modern TCD. 1st ed. Beijing: People's Medical Publishing House; 2001. p. 580-1.
6. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell. 2003;112:599-606.
7. Caldas C, Aparicio S. Cell memory and cancer - the story of the trithorax and Polycomb group genes. Cancer Metastasis Rev. 1999;18:313-29.
8. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62:4499-506.
9. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-9.
10. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62:4736-45.
11. Simon JA, Kingston RE. Mechanisms of Polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009;10:697-708.
12. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of zeste protein. Genes Dev. 2002;16:2893-905.
13. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002;298:1039-43.
14. Zeidler M, Kleer CG. The Polycomb group protein enhancer of zeste 2: its links to DNA repair and breast cancer. J Mol Histol. 2006;37:219-23.
15. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer. 2005;92:1754-8.
16. Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, et al. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer. 2006;95:1202-11.
17. Chen Y, Lin MC, Wang H, Chan CY, Jiang L, Ngai SM, et al. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics. 2007;7:3097-104.
18. Balasubramanian S, Chew YC, Eckert RL. Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells. Mol Pharmacol. 2011;80:870-8.
19. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, Eckert RL. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis. 2011;32:1525-32.
20. Fu J, Ma JY, Zhang XF, Wang Y, Feng R, Chen YC, et al. Identification of metabolites of davidiin, a potential antitumor ellagitannin, transformed by rat intestinal bacteria in vitro, based on liquid chromatography-ion trap-time of flight mass spectrometry analysis. J Pharm Biomed Anal. 2012;71:162-7.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:45.
22. Han YH, Moon HJ, You BR, Park WH. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009;22:215-21.
23. Liao SG, Zhang LJ, Sun F, Zhang JJ, Chen AY, Lan YY, et al. Antibacterial and anti-inflammatory effects of extracts and fractions from Polygonum capitatum. J Ethnopharmacol. 2011;134:1006-9.
24. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100:11606-11.
25. Lee K, Adhikary G, Balasubramanian S, Gopalakrishnan R, McCormick T, Dimri GP, et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol. 2008;128:9-17.
26. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050-63.